Generic drugmaker Teva Pharmaceutical Industries said on Tuesday that it had proposed buying rival Mylan for $82.00 per share in a mix of stock and cash.

Teva said the offer was a 48 per cent premium to the stock price of Mylan on March 10th, 2015, which it said was “the last day of trading prior to widespread speculation of a transaction between Teva and Mylan”.

Reuters